APA (7th ed.) Citation

S, A., K, N., YM, K., & F, A. (2013). Thrombus-targeted nanocarrier attenuates bleeding complications associated with conventional thrombolytic therapy. Pharmaceutical research, 30(6), 1663. https://doi.org/10.1007/s11095-013-1011-x

Chicago Style (17th ed.) Citation

S, Absar, Nahar K, Kwon YM, and Ahsan F. "Thrombus-targeted Nanocarrier Attenuates Bleeding Complications Associated with Conventional Thrombolytic Therapy." Pharmaceutical Research 30, no. 6 (2013): 1663. https://doi.org/10.1007/s11095-013-1011-x.

MLA (9th ed.) Citation

S, Absar, et al. "Thrombus-targeted Nanocarrier Attenuates Bleeding Complications Associated with Conventional Thrombolytic Therapy." Pharmaceutical Research, vol. 30, no. 6, 2013, p. 1663, https://doi.org/10.1007/s11095-013-1011-x.